Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(−2), epirubicin 100 mg m(−2) and cyclophosphamide 500 mg m(−2), six cycles every 21 days), to an epirubicin–vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients. Patie...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kerbrat, P, Roché, H, Bonneterre, J, Veyret, C, Lortholary, A, Monnier, A, Fumoleau, P, Fargeot, P, Namer, M, Chollet, P, Goudier, M-J, Audhuy, B, Simon, H, Montcuquet, P, Eymard, J-C, Walter, S, Clavère, P, Guastalla, J-P
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2007
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2359910/
https://ncbi.nlm.nih.gov/pubmed/17505516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603773
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires